In January 2018, LEITAT will become a core member of EIT Health, upgrading its current membership. LEITAT will join other core members such as the University of Barcelona, Karolinska Institute, Roche, and ATOS, among others.
This development comes at a time when EIT Health funding is expected to increase to €80-100 million per year by 2022, with the goal of creating significant impact, as stated by Sylvie Bove, CEO of EIT Health, in an interview with Biocat.
